2-氯-5-氟烟腈 | 791644-48-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氯-5-氟烟腈
• 中文别名: 2-氯-5-氟吡啶-3-甲腈；2-氯-3-氰基-5-氟吡啶
• 英文名称: 2-chloro-5-fluoronicotinonitrile
• 英文别名: 2-chloro-5-fluoropyridine-3-carbonitrile；2-chloro-5-fluoro-3-pyridinecarbonitrile
• CAS: 791644-48-9
• 化学式: C₆H₂ClFN₂
• 分子量: 156.547
• InChiKey: SUBZTZVHVGYOPM-UHFFFAOYSA-N

物化性质

• 沸点：
  235℃
• 密度：
  1.43
• 闪点：
  96℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• 海关编码：
  2933399090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-5-fluoronicotinonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-5-fluoronicotinonitrile
CAS number: 791644-48-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H2ClFN2
Molecular weight: 156.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-5-氟烟腈 在 四(三苯基膦)钯 、 palladium 10% on activated carbon 、 三氟化硼乙醚 、 氢气 、 六正丁基二锡 、 caesium carbonate 、 一水合肼 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 吡啶 、 二氯甲烷 、 乙二醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 维利西呱
  参考文献：
  名称：

  USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES

  摘要：

  本发明涉及利用可溶性鸟苷酸环化酶的激动剂和活化剂治疗镰状细胞贫血以及保存血液替代物的新方法。此外，本发明还涉及利用可溶性鸟苷酸环化酶的激动剂和活化剂与磷酸二酯酶5抑制剂结合治疗镰状细胞贫血以及保存血液替代物的方法。

  公开号：

  US20130158028A1
• 作为产物：
  描述：

  2,6-二氯-5-氟烟酸 在 palladium diacetate 、 N,N-二甲基甲酰胺 、 三苯基膦 甲酸 、 草酰氯 、 三乙胺 、 三氟乙酸酐 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 2-氯-5-氟烟腈
  参考文献：
  名称：

  AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES

  摘要：

  本发明涉及用作蛋白激酶抑制剂的化合物。该发明还提供包含这些化合物的药用合适组合物，以及在治疗各种疾病、症状和障碍中使用这些化合物和组合物的方法。该发明还提供制备本发明化合物的方法。

  公开号：

  US20110020377A1

文献信息

• [EN] TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR<br/>[FR] COMPOSÉS DE TRIAZOLE FURANE UTILISÉS EN TANT QU'AGONISTES DU RÉCEPTEUR APJ
  申请人：AMGEN INC

  公开号：WO2018097944A1

  公开（公告）日：2018-05-31

  Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.

  式(I)和式(II)的化合物，其药用盐，任何上述化合物的立体异构体，或它们的混合物是APJ受体的激动剂，并且在治疗心血管和其他疾病方面有用。式(I)和式(II)的化合物具有以下结构：(I); (II)。中间体(V)也被要求。
• [EN] THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS<br/>[FR] THIÉNOPYRIDINE CARBOXAMIDES UTILISÉS COMME INHIBITEURS DE PROTÉASE SPÉCIFIQUE DE L'UBIQUITINE
  申请人：FORMA THERAPEUTICS INC

  公开号：WO2017139778A1

  公开（公告）日：2017-08-17

  The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula (I), where R1, R2, R3, R4, R5, R5', R6, R7, X, m, and n are described herein.

  该披露涉及抑制剂USP28和/或USP25，用于治疗癌症、炎症、自身免疫疾病和传染病，具有式(I)，其中R1、R2、R3、R4、R5、R5'、R6、R7、X、m和n如本文所述。
• A modified approach to C-14-labeled 2-(3,4-difluorophenoxy)-5-fluoronicotinic acid and other halogen-substituted analogs
  作者：Yinsheng Zhang、Zhigang Jian、Wayne T. Stolle

  DOI：10.1002/jlcr.1887

  日期：2011.6.15

  A modified approach to a carbon-14-labeled pyridine ring system was developed based on the electrocyclic ring-closure of 1,4,4-trisubstituted butadiene. The new method was applied to prepare 2-(3,4-difluorophenoxy)-5-fluoro-[2-14C] nicotinic acid and other halogen-substituted analogs. The targeted compound was isolated with a radiochemical purity of >98% and a specific activity of 53 mCi/mmol from four radiochemical steps, starting from ethyl [1-14C] cyanoacetate in an overall radiochemical yield of 39%. Copyright © 2011 John Wiley & Sons, Ltd.

  基于1,4,4-三取代丁二烯的电环合闭环反应，开发了一种改良的碳-14标记吡啶环系方法。该新方法应用于制备2-(3,4-二氟苯氧基)-5-氟-[2-14C]尼古丁酸及其他卤素取代的类似物。从乙基[1-14C]氰基乙酸酯出发，经过四步放射化学步骤，总放射化学产率为39%，分离得到了目标化合物，其放射化学纯度>98%，比活度为53 mCi/mmol。版权所有 © 2011 John Wiley & Sons, Ltd。
• [EN] INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY<br/>[FR] INHIBITEURS DE TRYPTOPHANE DIOXYGÉNASES (IDO1 ET TDO) ET LEUR UTILISATION EN THÉRAPIE
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2016024233A1

  公开（公告）日：2016-02-18

  Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.

  描述了包含具有IDO1和/or TDO抑制活性的3-氨基异恶唑啉化合物I的药物组合物，其中W是CR1，N或N-氧化物；X是CR2，N或N-氧化物；Y是CR3，N或N-氧化物；Z是CR4，N或N-氧化物；W、X、Y和Z中的至少一个是N或N-氧化物；R9和R10如所定义。还描述了使用这些化合物治疗各种疾病，如癌症的方法。
• [EN] SUBSTITUTED IMIDAZOTRIAZINES<br/>[FR] IMIDASOTRIAZINES SUBSTITUÉES
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2011011712A1

  公开（公告）日：2011-01-27

  This invention relates to novel substituted imidazotriazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound showing partial-agonist activity at the GABA α2, α3 and α5 subtype receptors, and antagonist activity at the αl subtype receptor.

  这项发明涉及新型取代咪唑三嗪及其药用盐。该发明还提供了包括本发明化合物的组合物，并将这种组合物用于治疗通过给予显示GABA α2、α3和α5亚型受体部分激动剂活性和α1亚型受体拮抗活性的化合物有益治疗的疾病和症状的方法。